Abstract: Example methods of manufacturing a glass mirror apparatus includes the step of providing a chemically strengthened glass sheet with a thickness of less than or equal to about 2 mm. The method further includes the step of applying a reflective layer to the second major surface of the glass sheet to provide a first glass mirror. In further examples, a glass mirror apparatus comprises a chemically strengthened glass sheet with a thickness of less than or equal to about 2 mm. A reflective layer applied to the second major surface of the glass sheet to provide a first glass mirror.

Abstract: The present invention provides compounds of formula I, wherein the variables R1, R2, R5 and b are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Approaches for facilitating spatial and temporal verification of users and/or user devices are disclosed. In some implementations, a user device may be detected within a short wireless communication range. A wireless communication session with the user device may be initiated based on the detection. Information identifying a first integrity-based certificate may be received from the user device during the wireless communication session during a first time period. Information identifying a second integrity-based certificate associated with a second time period may be provided responsive to determining that the first integrity-based certificate is a valid integrity-based certificate associated with the first time period. The second integrity-based certificate may be configured to allow network access for the user device during the second time period.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for providing ranked search results responsive to a query. In one aspect, a method includes receiving, from a user device, a query specifying an entity, determining two or more resources each of which provide media content related to the entity, for each of the resources, determining an effectiveness measure that is a measure of the effectiveness of the resource to present, to a user of the user device, the media content related to the entity, ranking the resources using, at least in part, the respective effectiveness measure, and providing, to the user device, a presentation of search results for the ranked resources.

Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A method and system for sharing information between independent agents having a processor and memory having instructions stored thereon that, when executed by the processor, cause the system to receive signals indicative of a fault of a sensor system of a first independent agent; transmit signals indicative of a request for sensor information to a second independent agent; receive signals indicative of state information for the second independent agent in response to the receiving of the request for sensor information; and apply the state information to a navigation system of the first independent agent in response to the receiving of the state information.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

Abstract: Systems and methods for automatically generating targeting information for presentation of an offer in accordance with embodiments of the invention are disclosed. One embodiment includes indexing member profiles within one or more social networks for affinity to keywords using a targeting system that retrieves data concerning member profiles and activities from servers within an online social network, identifying member profiles that have affinity for at least one offer keyword using the targeting system and the index, identifying additional keywords for which the identified member profiles have affinity using the targeting system and the index, determining a set of keywords that target a desired audience based upon the identified additional keywords using the targeting server, and targeting presentation of advertisements for the specific offer to members of an online social network using the online social network and the targeting keywords determined by the targeting server.

Abstract: The invention relates to methods and systems for receiving, processing and fulfilling remotely placed orders. In one aspect, requests to place an order are received from a remote location, and based on a customer identifier included in the request, customer preference data is retrieved. An electronic selection menu based on customer preference data is transmitted to the customer, the order is received and prepared. The customer's arrival is automatically detected, and the completed order is provided to the customer.

Abstract: Hydroswellable, absorbable and non-absorbable, aliphatic, segmented polyurethanes and polyurethane-urea capable of swelling in the biological environment with associated increase in volume of at least 3 percent have more than one type of segments, including those derived from polyethylene glycol and the molecular chains are structurally tailored to allow the use of corresponding formulations and medical devices as carriers for bioactive agents, rheological modifiers of cyanoacrylate-based tissue adhesives, as protective devices for repairing defective or diseased components of articulating joints and their cartilage, and scaffolds for cartilage tissue engineering.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A magnetic wall cover system that includes an inner cover made at least partially of a ferrous material. The inner cover has an outer alignment surface. The magnetic wall cover system also has an outer cover that has an inner alignment surface. The outer cover is adapted to be removably mounted on the inner cover such that the inner alignment surface is in engaging relationship to the outer alignment surface when the outer cover is mounted over the inner cover. The magnetic wall cover system also includes at least one magnet disposed on the outer cover. The magnet is adapted to form a magnetic attraction between the magnet and the ferrous material of the inner cover.

Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.